Drug Profile
ORC 13661
Alternative Names: DB 041; ORC-13661Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator University of Washington
- Developer Oricula Therapeutics
- Class Amides; Chlorobenzenes; Heterocyclic bicyclo compounds; Phenylurea compounds; Small molecules; Thiophenes
- Mechanism of Action Cell death inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Sensorineural hearing loss
Most Recent Events
- 15 Feb 2023 Oregon Health and Science University plans a phase II trial for amikacin induced sensorineural hearing loss (Prevention, Adjunctive treatment, In adults, In the elderly) in USA (PO, Capsule) (NCT05730283)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Sensorineural hearing loss(Prevention, In volunteers) in USA (PO)
- 06 Mar 2019 Chemical structure information added